Fair balance is the requirement that promotional content for a prescription drug presents risk information with prominence and readability comparable to its benefit information. In the US it comes from FDA's advertising regulation, 21 CFR 202.1(e), which lists failing to present a fair balance between effectiveness and risk as one of the ways an advertisement can be false or misleading. It applies to advertising and promotional labeling, to consumer and HCP audiences, and to every channel.
It is also, year after year, the issue at the centre of FDA enforcement. Omission or minimization of risk was the most common theme in the letters FDA sent during its September 2025 crackdown on DTC advertising, and it has been a fixture of OPDP letters for as long as OPDP has issued them. This guide explains how fair balance is judged in practice, the patterns that usually cause content to fail, and a checklist for print, video, web, email and social.
What does fair balance actually require?
Fair balance is about presentation as much as content. Including the right risk information is necessary but not enough. The risks have to be presented with prominence comparable to the benefits: in a comparable position, at a comparable size and contrast, with comparable time on screen, and without competing elements that draw attention away from them.
The balance is judged across the whole piece. A benefit headline in large type at the top of a page is not balanced by risk information in small type at the bottom, even if the words are complete and correct. FDA looks at the net impression an asset creates for its audience, which is why two assets with identical text can be judged differently.
The risk information that matters is the material information from the approved labeling: a boxed warning if the product has one, contraindications, the most important warnings and precautions, and the most common adverse reactions. Fair balance also covers material facts about effectiveness itself, such as limitations of use in the indication. Leaving those out makes a claim misleading even when the claim is accurate.
Important Safety Information, the ISI block, is the industry’s standard way of carrying risk information in an asset, and print DTC ads carry the brief summary. Neither guarantees fair balance on its own. An asset with a complete ISI can still fail if its claims overstate the benefit or if its layout buries the risk.
How does FDA judge risk prominence?
The test is whether a reasonable member of the intended audience would come away with a balanced understanding of benefit and risk. In print and detail aids, reviewers look at type size, contrast, white space, placement relative to the claims, and whether the risk information is visually signalled as important or styled to be skipped.
In video, the questions are about timing and attention. Is the risk information delivered while upbeat music plays, while the scene cuts quickly, or while the visuals show a patient doing something the trial never measured? For TV and radio, FDA’s final rule on the major statement set a clear, conspicuous and neutral standard: consumer-friendly language, audio and on-screen text together in TV ads, and no distracting sounds or images while the risks are described. That is a good bar for every video format.
On the web, reviewers look at whether benefit claims are visible on arrival while the risks sit far below or behind a link, and whether the safety information remains visible as the user scrolls. Many brands use a persistent ISI panel for this reason. In social and search, where space is tight, FDA’s 2014 draft guidance on platforms with character limits says a post making a benefit claim should include the most serious risks in the same post, with a link to fuller information. If there is not enough space for both, the guidance suggests the platform may not suit the message.
What are the most common fair balance failures?
The most direct failure is omission: a banner, booth panel or social post that makes a benefit claim with no risk information at all. In February 2025, OPDP cited a convention booth panel for exactly this. Display ads and exhibit graphics are especially prone to it because they are designed to be read in seconds.
More often, the risk is present but minimized. It appears in smaller type, lighter colour or a cramped footer; it runs over fast cuts and loud music; it is introduced with language that downplays it; or the benefits are repeated several times while the risks appear once. Each of these can make an asset unbalanced without a single inaccurate word.
Overstated efficacy unbalances an asset from the other side. Calling a drug “proven” without specifying what was proven, presenting relative risk reductions without the absolute numbers, promoting secondary endpoints or subgroups as if they were primary results, and using imagery that implies benefits beyond the evidence all make the benefit look larger than the data support. No amount of risk information fixes that.
Finally, there is the omission of material facts about the indication: a claim that drops the population the drug is approved for, or a limitation of use that changes how a physician would read the benefit. These are easy to lose when copy is shortened for a new channel, which is why every adaptation needs its own check.
Fair balance by channel: a practical checklist
Print and detail aids: risk information on the same page or spread as the claims it balances, in readable type and contrast, with the full prescribing information accompanying HCP pieces. Avoid styling the safety section as a footer.
Video, TV and connected TV: the major statement delivered in plain language, in audio and on-screen text together, with no competing music, sound effects or fast cutting while it runs. Check that the visuals during the risk section are neutral, and that the benefit section does not show outcomes the label does not support.
Web and landing pages: risk information visible in the page, not only behind a link, and reachable without scrolling far past the claims. A persistent ISI panel is a common solution. Check every entry point, because users often land deep in a site from search or ads.
Email: safety information in the body of the email, not only linked. Treat subject lines and preview text as part of the content, because a benefit claim in a subject line is still a claim.
Social, search and display: the most serious risks in the same post or ad as any benefit claim, with a link to complete information. Reminder ads, which name the product without making any claim about what it does, are exempt from the risk requirements, but they are not permitted for products with a boxed warning. Influencer posts follow the same rules as any other company communication.
How to build fair balance into the workflow
Most fair balance problems are created at the design stage and discovered at review. The fix is to design for balance from the start. Write the risk section first, or at least alongside the claims, rather than fitting it into whatever space is left. Build templates that reserve space for safety information at a readable size, so no designer has to argue for it later.
Treat the ISI as an approved module: one controlled version per product and market, inserted into every asset rather than retyped. When the label changes, there is one module to update and a clear list of the assets that use it.
Ask reviewers to judge the net impression, not just the text. A short note in the submission explaining how balance is achieved, such as where risks appear, how long they run on screen and at what size, speeds up the review and shows the team has thought about it.
Magic Studio applies the same principle in every asset it makes. Content is written from your approved claims and dossiers, every claim is checked against the label for its market, and fair balance and safety information are placed as the asset is made, across Video, Docs, Ads, Approved Email and Web. Finished work then goes to your MLR reviewers, who make the final call.
Frequently asked questions
What is fair balance in pharma?
Fair balance is the FDA requirement that promotional content for a prescription drug presents risk information with prominence and readability comparable to its benefit information, so that the overall impression of the content reflects both the benefits and the risks.
Is fair balance the same as ISI?
No. Important Safety Information is the block of risk information many assets carry. Fair balance is the overall requirement that benefit and risk are presented in balance across the whole piece. An asset can include a complete ISI and still fail fair balance if its claims overstate the benefit or its layout minimizes the risk.
Does fair balance apply to HCP materials?
Yes. Fair balance applies to promotional content for healthcare professionals as well as consumers. HCP materials are also expected to be accompanied by the full prescribing information.
Do reminder ads need fair balance?
Reminder ads, which give the product name but make no claim about its use or effectiveness, are exempt from the risk information requirements. They are not permitted for prescription drugs with a boxed warning.
How should social media posts handle fair balance?
Following FDA's 2014 draft guidance on platforms with character space limitations, a post that makes a benefit claim should include the most serious risks within the same post and link to more complete risk information. If the platform does not leave room for both, it may not be suitable for that message.